OpGen, Inc. (Nasdaq:OPGN), an early commercial-stage molecular testing and bioinformatics company, today launched its expanded, comprehensive molecular testing and bioinformatics program for detecting and managing Gram negative multi-drug resistant organisms, or MDROs. These products and services are designed to enable healthcare providers to rapidly identify and help manage hospital patients who are colonized or infected with life-threatening, drug resistant organisms.
OpGen also announced that it has been selected to participate in the White House Forum on Antibiotic Stewardship, being held today in Washington, D.C. The event brings together key federal and private-sector constituencies involved in the development, promotion and implementation of antibiotic stewardship activities to ensure the responsible use of antibiotics nationwide. A live stream of the opening session will be available beginning at 8:00 a.m. Eastern time via www.whitehouse.gov/live.